CagriSema is a fixed-dose combination therapy comprising two molecules administered together in a single once-weekly subcutaneous injection: semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist already approved for weight management as Wegovy, and cagrilintide 2.4 mg, a long-acting analogue of amylin, a hormone involved in appetite regulation and satiety signalling
In an ideal world researchers who were not either taking money from a drug company or directly employed by, and shareholders, of them would evaluate drugs in trials with rigorous methodology, drawing unbiased conclusions
Malaguarnera M, Pistone G, Astuto M, DellArte S, Finocchiaro G, Lo Giudice E, Pennisi G
White bread, white pasta, white rice, and pastries are all examples of refined carbs, Dr
Cost-Effectiveness: Using single-use sterile water for a multi-day experiment would require discarding expensive peptides every single day